Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Abeona Granted Licenses to Develop Gene Therapies for Four Rare Disorders

By Abeona Therapeutics Inc. | November 6, 2018

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, has been granted new exclusive licenses to develop gene therapies for treatment of four rare lysosomal storage disorders using Regenxbio’s NAV AAV9 vector platform technology. 

The global licenses will help support development of gene therapies for treatment of Sanfilippo syndrome types A and B (MPS IIIA and MPSIIIB), infantile Batten disease (CLN1), and juvenile Batten disease (CLN3).

Under the terms of the agreement, Regenxbio has granted Abeona an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to Regenxbio’s NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease.

In return for the rights, Regenxbio will receive a guaranteed $20 million upfront payment, $10 million of which will be paid upon signing and $10 million of which will be paid within 12 months of the effective date. In addition, Regenxbio will receive a total of $100 million in annual fees, payable upon the second through sixth anniversaries of the agreement, $20 million of which is guaranteed. Regenxbio is also eligible to receive potential commercial milestone payments of up to $60 million. Regenxbio will receive low double-digit royalties on net sales of products incorporating the licensed intellectual property.

Sanfilippo syndrome is a group of rare genetic lysosomal storage diseases with no approved treatments. Infantile and juvenile forms of Batten disease are rare autosomal recessive genetic disorders with no approved treatments.

(Source: Abeona Therapeutics Inc.)

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards